美国大药企为何超百亿购中国一款药 PD-1/VEGF靶点受青睐

新浪
23 May

美国大药企为何超百亿购中国一款药 PD-1/VEGF靶点受青睐!截至2025年5月21日收盘,三生国健连续三个交易日涨停,涨幅达72.78%;子公司三生制药三天内上涨了63.66%。这主要因为美国辉瑞制药斥资近100亿元首付款,买下三生制药一款未上市的抗肿瘤药物。这款药物与康方生物的依沃西一样,靶点都是PD-1/VEGF。依沃西曾被高盛预测年销售峰值可达530亿美元。三生与辉瑞的这笔交易创下中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10